Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology by John P. M. Finberg & Jose M. Rabey
REVIEW
published: 18 October 2016
doi: 10.3389/fphar.2016.00340
Frontiers in Pharmacology | www.frontiersin.org 1 October 2016 | Volume 7 | Article 340
Edited by:
Rona R. Ramsay,
University of St. Andrews, UK
Reviewed by:
Angela J. Grippo,
Northern Illinois University, USA
Ken Gillman,
PsychoTropical, Australia
*Correspondence:
John P. M. Finberg
finberg@technion.ac.il
Specialty section:
This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 13 May 2016
Accepted: 12 September 2016
Published: 18 October 2016
Citation:
Finberg JPM and Rabey JM (2016)
Inhibitors of MAO-A and MAO-B in
Psychiatry and Neurology.
Front. Pharmacol. 7:340.
doi: 10.3389/fphar.2016.00340
Inhibitors of MAO-A and MAO-B in
Psychiatry and Neurology
John P. M. Finberg 1* and Jose M. Rabey 2
1 Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel, 2 Assaf Harofe Medical Center,
Affiliated to Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Inhibitors of MAO-A and MAO-B are in clinical use for the treatment of psychiatric
and neurological disorders respectively. Elucidation of the molecular structure of the
active sites of the enzymes has enabled a precise determination of the way in which
substrates and inhibitor molecules are metabolized, or inhibit metabolism of substrates,
respectively. Despite the knowledge of the strong antidepressant efficacy of irreversible
MAO inhibitors, their clinical use has been limited by their side effect of potentiation of
the cardiovascular effects of dietary amines (“cheese effect”). A number of reversible
MAO-A inhibitors which are devoid of cheese effect have been described in the
literature, but only one, moclobemide, is currently in clinical use. The irreversible inhibitors
of MAO-B, selegiline and rasagiline, are used clinically in treatment of Parkinson’s
disease, and a recently introduced reversible MAO-B inhibitor, safinamide, has also been
found efficacious. Modification of the pharmacokinetic characteristics of selegiline by
transdermal administration has led to the development of a new drug form for treatment
of depression. The clinical potential of MAO inhibitors together with detailed knowledge
of the enzyme’s binding site structure should lead to future developments with these
drugs.
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INTRODUCTION
Monoamine oxidase (MAO; EC 1.4.3.4.) is a widely distributed mitochondrial enzyme with high
expression levels in gastro-intestinal and hepatic as well as neuronal tissues. The enzyme catalyzes
the oxidative deamination of a variety of monoamines, both endogenous and exogenous, and has
major roles in metabolizing released neurotransmitters, and in detoxification of a large variety of
endogenous and exogenous amines. Drugs which inhibit MAO are currently in clinical use for
treatment of affective disorders and Parkinson’s disease (PD). In this chapter we review recent
developments in the basic pharmacology of MAO inhibitors (MAOI) and their clinical usage, and
discuss the potential for new drug development in this field.
The overall enzyme reaction of MAO can be represented by the following equation:
MAO
R− CH2 −NH2 +O2 +H2O = R− CHO+NH3 +H2O2
The aldehydes produced by the action of MAO are metabolized further by aldehyde dehydrogenase
and aldehyde reductase leading to the formation of glycols and carboxylic acids (Westfall and
Westfall, 2011). The fact that an aldehyde is formed initially together with H2O2 which can generate
reactive oxygen species (ROS) has drawn attention to the possibility that products of the action of
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MAO may be neurotoxic (Jenner, 2003). In this connection
it should be realized that ROS and other reactive species are
normally metabolized by scavenger enzymes including catalase
and superoxide dismutase, and dysfunction of these enzyme
systems may be a factor in neurodegenerative disease (Aluf
et al., 2011). The dopaminergic neurons of substantia nigra
pars compacta (SNpc) are at risk to oxidative stress because
of their tonic activity and dense packing. Their degree of
oxidative stress increases in early PD when a portion of the
neurons have been lost, and the activity of the remaining ones
increases in compensation. This situation was modeled recently
in a microdialysis study in which a non-diffusible indicator
molecule was perfused through a probe placed in the striatum.
Following intraventricular injection of 6-hydroxydopamine in a
dose adequate to reduce SNpc dopaminergic cell number by 50%,
the level of oxidative stress increased markedly (Aluf et al., 2011),
and was reduced following systemic injection of an MAO-A or
MAO-B inhibitor (Aluf et al., 2013).
MAO ISOFORMS
Two isoenzymes are encoded in the human X-chromosomal gene
Xp1 123, MAO-A, and MAO-B. The two forms have over 70%
homogeneity. Biochemically, the two forms can be differentiated
by their substrate and inhibitor specificities; MAO-A shows
greater affinity for hydroxylated amines such as noradrenaline
(NA) and serotonin (5-hydroxytryptamine, 5-HT), whereas
MAO-B shows greater affinity for non-hydroxylated amines such
as benzylamine and beta-phenylethylamine (PEA). The amines
dopamine (DA) and tyramine show similar affinity for each
enzyme form. Clorgyline is a selective inhibitor of MAO-A
while selegiline (l-deprenyl) and rasagiline are relatively selective
inhibitors of MAO-B. The ratio of selectivity of selegiline and
rasagiline for MAO-B is such that in human subjects, doses
2–5 fold higher respectively than the MAO-B selective dose can
cause significant inhibition of MAO-A as shown by tyramine
pressor responses (Bieck and Antonin, 1994; Goren et al.,
2010). Some inhibitors can inhibit both forms of the enzyme
(referred to as non-selective inhibitors, although this can cause
confusion because the inhibitors are quite selective for MAO
as opposed to other enzymes). The precise localization of the
two MAO isoforms in brain has not been completely elucidated.
Studies using cell cultures (Yu and Hertz, 1983; Carlo et al.,
1996) pointed to localization of MAO-A within glial cells, but
this is not true for the intact brain, where investigations in
both primate and non-primate species have established that
the glial enzyme is predominantly type B (Levitt et al., 1982;
Denney and Denney, 1985; Westlund et al., 1988). The type
A isoform has been localized to several neuronal cell types in
primate and rodent species, including NA-ergic neurons of the
locus coeruleus, DA-ergic neurons of the substantia nigra pars
compacta (SNpc), (Westlund et al., 1993) and striatal medium
spiny neurons (Sader-Mazbar et al., 2013). Serotonergic neuronal
cell bodies of the raphe nucleus stain positive for MAO-B but
the isoform localized to axonal varicosities may be of the A
isoform (Denney and Denney, 1985). Selective inhibition of
MAO-A leads to increased levels of neurotransmitter within
noradrenergic (NA-ergic) and 5-HT-ergic neurons of the CNS,
and clinical antidepressant action, while inhibition of MAO-
B leads to increased levels of DA in the Parkinsonian brain
with partial depletion of DA-ergic neurons in SNpc, and anti-
Parkinsonian action (see Finberg, 2014 for a detailed description
of these events at the synaptic level).
Many compounds with MAO inhibitory properties are being
prepared by researchers, however the present account is limited
to a description of the most important drugs from a therapeutic
viewpoint, i.e., affective disorders and Parkinson’s disease. The
chemical structures of drugs mentioned in this review and a brief
description of their major characteristics is shown in Table 1.
MOLECULAR STRUCTURE OF MAO AND
MECHANISM OF ENZYME INHIBITION
For many years, a formula was searched for without success
to explain the selectivity of an inhibitor molecule for MAO-A
or MAO-B. The problem was solved when the MAO protein
molecule was crystallized by the groups of Edmondson and
Sukihara, enabling three-dimensional modeling of the protein
and its combining site (Binda et al., 2002, 2007; De Colibus
et al., 2005; Son et al., 2008). It was then seen that a two-site
cavity structure exists for human MAO-B (hMAO-B), with an
entry cavity and a reactive site cavity, whereas in humanMAO-A
(hMAO-A) the active site cavity is not bipartite and is shorter
and wider than the longer and narrower substrate cavity in
hMAO-B (De Colibus et al., 2005). The reactive site contains a
combining moiety in which the N5 atom of FAD is displayed
on the inner surface, and tyrosines 398, and 435 guard the entry
gate in hMAO-B (Binda et al., 2002). Knowledge of the three-
dimensional aspects of these sites, and the associated amino acid
positions, can now be utilized in the design of new inhibitors.
Both reversible and irreversible inhibitors of MAO have been
developed in previous years, and are currently in use clinically
for treatment of affective and neurological disorders. Irreversible
inhibitors are of several types: hydrazines, cyclopropylamines,
and propargylamines. In all cases, these drugs combine covalently
with the N5 atom of the flavin residue, but the rate of dissociation
of the drug-enzyme complex is variable. Detailed mechanisms
for the drug-enzyme complex formation have been described.
Following recognition of the enzyme pharmacophore by the
drug, the inhibitor molecule is metabolized leading to a reactive
intermediate which combines covalently with the N5 atom of
FAD leading to formation of a drug-receptor adduct, which then
undergoes aging and irreversible combination. The term “suicide
inhibitor” has been used in description of this type of drug action
(see Finberg, 2014).
In general, because these inhibitors will irreversibly inactivate
the enzyme, their action can only be reversed by generation
of new enzyme molecules, a process which can take days or
weeks. In clinical use, the drugs are administered daily, using
a dose which alone is adequate to cause only partial enzyme
inhibition, but when given daily over several days will cause a
cumulative inhibition up to 90% or more of the target enzyme in
brain. Continued drug administration ensures that newly-formed
enzymemolecules are also inhibited, and that the enzyme activity
is maintained at a constant low level. The clinical importance of
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TABLE 1 | Structures and major characteristics of MAO inhibitors mentioned in the text.
Compound Activity Status Chemical structure
Phenelzine Irreversible MAO-A + MAO-B Used as antidepressant Hepatotoxicity Needs dietary
control for restriction of tyramine intake
Tranylcypromine Irreversible MAO-A + MAO-B Used as antidepressant with dietary control
Pargyline Irreversible MAO-A and MAO-B Antidepressant and antihypertensive Currently not in
clinical use
Selegiline Irreversible MAO-B selective (R- enantiomer) Selectivity is
dose dependent in vivo
Metabolism to amphetamines
Clorgyline Irreversible highly MAO-A selective Antidepressant effect demonstrated in humans but not in
clinical use
Moclobemide Reversible highly MAO-A selective Moderately effective antidepressant drug
Rasagiline Irreversible MAO-B selective (R+ enantiomer) Selectivity
is dose dependent in vivo
Neuroprotective in vitro, anti-Parkinson drug, metabolism
to 1-aminoindan
Safinamide Reversible highly MAO-B selective Anti-Parkinson drug, glutamate receptor antagonistic
and Na+ channel blocking properties
Ladostigil MAO-A + MAO-B Relative brain selectivity, minimal
tyramine potentiation
Cholinesterase and MAO inhibition
VAR 10303 MAO-A + MAO-B Relative brain selectivity, minimal
tyramine potentiation
Fe chelation and MAO inhibition
M30 MAO-A and MAO-B Relative brain selectivity Fe chelation and MAO inhibition
this type of drug use is that a constant high degree of enzyme
inhibition can be maintained over time. In addition, however, on
stopping treatment enzyme activity will remain at a low level even
after the drug itself has been cleared from the body.
TREATMENT OF DEPRESSION WITH MAO
INHIBITORS
Non-subtype-Selective Irreversible
Inhibitors
The profound antidepressant action of MAOI inhibitors
was discovered by chance (Lehmann and Kline, 1983) in
tuberculous patients treated with iproniazid, a derivative of the
hydrazine compound isoniazid. Further developments led to the
introduction into clinical use of several non-subtype-selective
irreversible MAO inhibitors including the hydrazines phenelzine
and isocarboxazid, the propargylamine pargyline, and the
cyclopropylamine tranylcypromine, but these compounds can all
lead to potentiation of the cardiovascular effects of the dietary
amine tyramine (“cheese effect”). Following realization that the
cheese effect can be avoided by dietary counseling, and that
MAO inhibitors are in fact excellent drugs for treatment of drug-
resistant and atypical depression, use of certain non-subtype-
selective inhibitors, in particular tranylcypromine (Parnate),
is now seen with increasing frequency. Tranylcypromine has
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pharmacological properties in addition to inhibition of MAO,
in particular inhibition of lysine-specific histone demethylation
type 1, and interaction with the endogenous cannabinoid system
(Lee et al., 2006; Hill et al., 2008). Phenelzine also has an
additional pharmacological property which may be involved in
its antidepressant actions, namely blockade of GABA and alanine
transaminases (Baker et al., 1991; Todd and Baker, 2008).
In a recent review (Heijnen et al., 2015) of a small number
of clinical trials, tranylcypromine was found to be an efficacious
and safe drug for the treatment of bipolar depression, when
administered with correct dietary counseling. Although cheese
effect is a potentially serious reaction, the limitations it imposes
on treatment of psychiatric patients have beenmuch exaggerated,
because the amounts of tyramine occurring in foodstuffs are quite
low, and only a gross violation of normal dietary directions would
be likely to cause a fatal, or damaging, reaction (Gillman, 2011).
The management of such a hypertensive reaction if it does occur
has also been well-documented (Gillman, 2011). In addition
to cheese effect, another potential danger is serotonin toxicity
syndrome (ST), which can occur following the combination
of irreversible MAOI with a drug which has the potential
to elevate 5-HT synaptic levels, such as a serotonin-selective
reuptake inhibitor (SSRI) (Gillman, 2006). In this context, the
relatively long period required for return of MAO activity
following cessation of therapy with an irreversible inhibitor is
important when a change in therapy is required. If therapy
with a SSRI is to be used, there is a danger of ST if these
drugs are instituted before MAO activity has returned to normal
levels. Following cessation of tranylcypromine administration in
healthy subjects, a period of 30 days was required for complete
normalization of the pressor response to oral tyramine challenge
(Bieck and Antonin, 1988). In the case of rasagiline, using platelet
activity of MAO-B as the index, enzyme activity returned to
baseline levels 2 weeks after cessation of drug administration in
healthy subjects (Thebault et al., 2004). The time required for
return of enzyme activity in the brain however, is considerably
longer than in the periphery. Using (Denney and Denney, 1985)
C-labeled selegiline together with positron emission tomography
(PET) the half-time for return of MAO-B binding in the brain
following complete blockade of binding by an initial injection
of selegiline in a baboon was 30 days (Arnett et al., 1987), and
using similar technique, following initial MAO-B inactivation
by rasagiline in human subjects, was 40 days (Freedman et al.,
2005). Recommended periods (by manufacturer) for wash-out
after cessation of tranylcypromine range from 7 to 10 days (Gahr
et al., 2013).
The antidepressant effect of MAOI has focused interest on
the possibility that altered expression levels of the MAO enzyme
could be the cause of some forms of depressive disorders.
Polymorphisms in the MAO-A gene have been associated with
a number of behavioral traits. Reduced enzyme activity is
associated with violent behavior and aggression, whereas over-
expression may be linked to depression (Alia-Klein et al., 2008).
These facts, together with the well-known biogenic amines
hypothesis, provide theoretical background in support of the use
of MAOI for treatment of affective disorders. Several studies have
attempted to link the MAOA-uVNTR polymorphism, which
leads to increased enzyme transcription, with suicidal tendency,
but a meta-analysis including 1452 psychiatric patients and 1198
control subjects did not find a significant association (Hung et al.,
2012) with this particular trait. In a recent study in which MAO-
A expression level (total distribution volume, Vt, of 11C-harmine
by PET) was determined in borderline personality disorder
(BPD) patients, the MAO-A brain content was correlated with
symptom severity (Kolla et al., 2015). Interestingly, MAO-A Vt
was increased in prefrontal cortex and anterior cingulate cortex
by 43 and 42% respectively in severe BPD subjects in relation to
controls.
One of the main restrictions to the clinical use of MAOI
for treatment of depression is the cheese effect. In preclinical
and clinical studies it was shown that potentiation of the
pharmacological effects of tyramine occurs following selective
inhibition of MAO-A but not MAO-B (Lader et al., 1970; Finberg
and Tenne, 1982; Finberg and Gillman, 2011). This can be
attributed to the localization of MAO-A to noradrenergic (as well
as serotonergic) neurons (see Finberg, 2014) for detailed review).
A corollary to this selective localization of MAO subtypes
is that selective inhibitors of MAO-A but not MAO-B are
effective antidepressants (Youdim and Finberg, 1983), however
no irreversible selective MAO-A inhibitors are in use for
treatment of depression.
Reversible Inhibitors of MAO-A
In the 1980s several groups of researchers prepared selective
reversible inhibitors of MAO-A (RIMAs) (Tipton et al., 1984)
based on the theory that if substrate levels increased as a result of
inhibition of the enzyme, the degree of enzyme inhibition would
be reversed by increased dissociation of the inhibitor from its
combining site, i.e., a reversible inhibitor would possess a built-
in safety factor in the case of tyramine ingestion, and therefore
reversible inhibitors would not cause cheese effect (Finberg,
2014). The correctness of this notion was confirmed in a number
of clinical studies using tyramine challenges in patients (Finberg
and Gillman, 2011; Finberg, 2014). Currently, moclobemide
is the only RIMA available for clinical use. Although clinical
studies carried out in the period following its general release
showed an efficacy similar to that of tricyclic antidepressants
(TCA) for treatment of depression it was found less effective
than irreversible MAOIs (Lotufo-Neto et al., 1999; Shulman
et al., 2013). Another reversible selective MAO-A inhibitor
with antidepressant properties is methylene blue (Naylor et al.,
1987; Ramsay et al., 2007). This interesting drug has several
pharmacological actions, including inhibition of nitric oxidase
synthase (NOS), and guanylate cyclase (Harvey et al., 2010), and
so its antidepressant properties should not be solely ascribed to
inhibition of MAO-A.
Selective Inhibitors of MAO-B in Treatment
of Depression and Attention Deficit
Hyperactivity Disorder (ADHD)
Following introduction of the irreversible selective MAO-B
inhibitor selegiline for treatment of PD (see following sections),
its efficacy for treatment of depression was examined in several
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uncontrolled clinical trials, using the MAO-B-selective dose
of 10mg daily, and as was anticipated following the known
involvement of mainly serotonergic and noradrenergic neuronal
systems in depression, it was not effective. When examined
at the higher doses of 30 or 60mg daily, however, it did
have significant antidepressant effect, especially in treatment-
resistant depression (Mann et al., 1989; Sunderland et al.,
1994). Based on these positive results a pharmacokinetic strategy
was developed (selegiline transdermal system, STS) which
permits a greater portion of the administered dose to enter
the CNS, and reach tissue levels concomitant with inhibition
of both MAO-A and MAO-B while avoiding inactivation of
gastro-intestinal and hepatic enzyme (Mawhinney et al., 2003).
This technique was developed on the basis of preclinical
experiments in guinea-pigs (Mawhinney et al., 2003). In order
to understand the mechanism of this relative brain selectivity,
it is necessary to understand: (a) that selegiline is only MAO-
B selective at low dose, and higher doses will inhibit both
MAO-A and MAO-B, and (b) the pharmacokinetics of selegiline
(Magyar, 2011). This compound is based on the molecule of
R(−)methamphetamine, and following systemic administration
it is metabolized by cytochrome P450 enzymes in the liver,
mainly to R(−)methamphetamine, R(−)amphetamine, and N-
desmethylselegiline (Laine et al., 2000; Azzaro et al., 2007). When
administered transdermally the first-pass metabolism is largely
avoided, and a larger part of the administered dose directly
accesses the brain, and binds irreversibly to both MAO-A and
MAO-B. Intact molecules of the drug which leave the brain
will be metabolized in the liver, but large scale inhibition of
MAO isoforms in gastro-intestinal tract and liver will be avoided
(Mawhinney et al., 2003), and the formation of potentially
damaging amphetamines is reduced. The success of this strategy
has been confirmed in human experiments, in which it was
shown: a) that STS is an effective antidepressant, and b) that
at antidepressant doses it does not cause cheese effect (Azzaro
et al., 2006; Blob et al., 2007). Another dose form of selegiline
aimed to produce a similar alteration in pharmacokinetics of
the drug is the buccally administered solution (Zydis selegiline)
which similarly produces effective antidepressant activity without
significant tyramine potentiation (Clarke et al., 2003a,b). Its
improved pharmacokinetics permit the use of lower doses
which confer greater selectivity for MAO-B over MAO-A
inhibition. The MAO-B-selective inhibitor rasagiline has been
found effective in treatment of PD depression with a greater
response at 2 mg/day than the usual dose of 1 mg/day, possibly
because of the greater inhibitory effect on MAO-A at the higher
dose (Korchounov et al., 2012).
In preclinical studies in rats, rasagiline administered at
selective MAO-B-inhibitory dose did not modify DA, NA
or 5-HT levels or induce reserpine reversal (Finberg and
Youdim, 2002), however in aged mice, chronic administration
of an MAO-B-selective dose (0.2 mg/kg daily for 3 weeks)
did increase brain levels of DA and reduce DOPAC, and
also showed antidepressant-like effects. Interestingly, the drug
returned activity in behavioral paradigms such as learning and
forced-swim test, which were reduced in the aged animals, to
levels seen in young animals (Weinreb et al., 2015). It is of interest
that these effects of rasagiline in aged mice were produced also by
chronic administration of its major metabolite 1-aminoindan, at
a dose of 5 mg/kg daily over 3 months (Badinter et al., 2015).
The authors of these articles suggested that the effects of 1-
aminoindan indicate an action on catecholaminergic systems
which is not the result of MAO inhibition, because ex vivo brain
MAO activity was not inhibited; however since it is a reversible
MAO inhibitor (Binda et al., 2005) their ex vivo assay of MAO
would not be expected to show a change in enzyme activity,
because the drug would be washed out or diluted in the brain
homogenate used in their assay. On the other hand, the changes
in tissue monoamine levels and their metabolites (Mann et al.,
1989) are indicative of an inhibition of MAO.
In a placebo-controlled study of 11 children with ADHD
selegiline significantly improved attention but not impulsivity
(Akhondzadeh et al., 2003; Niederhofer, 2003; Rubinstein et al.,
2006). In three studies in which selegiline was compared
with methylphenidate in children with ADHD, the two drugs
had similar efficacy (Akhondzadeh et al., 2003; Niederhofer,
2003; Mohammadi et al., 2004). Considering the detrimental
pharmacology of amphetamine-like drugs used in ADHD, the use
of MAO-B inhibitors in this condition warrants further study.
Since MAO-B inhibition markedly increases the brain levels of
endogenous PEA (“the body’s own amphetamine”), this could be
an explanation for the selegiline effects observed in the above
studies, in addition to inhibition of DA breakdown.
MAOI and Drug Addiction
Use of MAOI in treatment of depression in cocaine-
addicted subjects has been proposed, because chronic
cocaine administration reduces the activity of monoamine
neurotransmitter systems, which are enhanced by MAOI. In
addition, by enhancing DA levels MAOI could possibly be used
to substitute for the reward-initiating effect of cocaine (Ho
et al., 2009). The potential of MAOI to reduce cocaine-induced
reward was studied in mice (Ho et al., 2009). The long-term
administration of both selegiline (1 mg/kg i.p. daily for 3 weeks)
and pargyline (10 mg/kg i.p. daily for 3 weeks) abolished cocaine-
supported operant responses whereas long-term treatment with
clorgyline (2 mg/kg i.p. daily for 3 weeks) did not. It should
be noted that the doses of selegiline and pargyline used were
probably adequate to inhibit both MAO-A and MAO-B,
as shown by their reduction of dihydroxyphenylacetic acid
(DOPAC) and 5-hydroxyindole acetic acid (5-HIAA) levels
in frontal cortex, while clorgyline enhanced 5-HT but did not
reduce 5-HIAA levels in frontal cortex. The authors proposed
that the use of MAO-B inhibitors to curb cocaine reward should
be further considered. In a pilot study in human subjects, 10mg
p.o. selegiline daily reduced cocaine consumption but in a
subsequent larger study (300 subjects) transdermal selegiline did
not significantly reduce consumption. An additional study with
transdermal selegiline reduced cocaine-related scores of anger
and tension as well as craving but also did not reduce subjective
reported rewarding effects of a higher dose of cocaine compatible
with binge use in humans (Elkashef et al., 2006; Harris et al.,
2009). Clinical studies have not found evidence of abuse liability
in humans (Yasar et al., 1996), and in addition it should be noted
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that selegiline does not induce addictive behavior in monkeys
(Winger et al., 1994).
Pharmaco-Therapy of PD Depression
There are a number of considerations relating to the pharmaco-
therapy of PD depression, including the stage of the disease,
possible interactions with other medications (especially L-dopa,
LD), control of the autonomic nervous system, and the disturbed
normal balance between the monoamine systems of the brain.
In addition, the possibility of cognitive deficits and PD dementia
will confuse the understanding of the patient’s affective state. In a
meta-analysis of 11 controlled clinical trials for pharmacological
treatments in PD depression between the years 2004 and 2014
(Sandoval-Rincon et al., 2015), rasagiline was found effective, but
at the dose of 2 mg/day, which is higher than the usual dose of
1mg daily for PD symptomatology.
For advice to clinicians on the ins and outs of treatment of
depression with MAOIs, the reader is referred to recent reviews
(Cohen and Sclar, 2012; Goldberg and Thase, 2013; Shulman
et al., 2013).
NEUROPROTECTIVE ACTIONS OF MAOI
All MAOI possess inherent neuroprotective properties because
of their inhibition of H2O2 and toxic aldehyde release
following oxidative metabolism of amines, however individual
inhibitors may possess an intrinsic neuroprotective action
in addition. Selegiline was found by Knoll and co-workers
to increase the natural life-span of laboratory rats, and
subsequently was found to exert an anti-apoptotic effect
in a variety of tissues and cells which was independent
of MAO inhibition (Tatton and Chalmers-Redman, 1996).
It is important to note that the anti-apoptotic properties
of desmethylselegiline (the selegiline metabolite which is
the active neuroprotective molecule) are superior to those
of selegiline, and that R(−)methamphetamine, the major
metabolite of selegiline, antagonizes the neuroprotective property
of selegiline and desmethylselegiline (Tatton and Chalmers-
Redman, 1996). Subsequently, rasagiline was found to also
possess neuroprotective properties both in vivo (Aluf et al.,
2013) and in vitro (Finberg et al., 1998; Weinreb et al.,
2011). Both these molecules increase BCl2 and PKC-epsilon
levels, enhance synthesis and release of BDNF and GDNF,
and activate additional anti-apoptotic mechanisms (Jenner and
Langston, 2011). It is a current unsolved mystery why these
small molecules should exert these complex pro-survival effects.
One series of studies produced evidence that selegiline binds
to GAPDH and prevents the nuclear translocation of this
enzyme (Carlile et al., 2000), however the tricyclic selegiline
derivative CGP3466 (Omigapil), which does not inhibit MAO,
binds GAPDH and prevents its nuclear translocation, possesses
anti-apoptotic activity in vitro and in vivo (Waldmeier et al.,
2000) but was not effective in clinical trials for PD and ALS.
Rasagiline also prevents the pro-apoptotic nuclear translocation
of GAPDH (Maruyama et al., 2001). The rasagiline metabolite
1(R)-aminoindan possesses anti-apoptotic activity (at higher
concentrations than the parent molecule), and shows a similar
spectrum of biochemical mechanisms as described for rasagiline
(Bar-Am et al., 2010), however the presence of the propargyl
moiety seems to be an important factor in neuroprotection,
since propargylamine itself also possesses anti-apoptotic activity,
albeit at higher concentrations than are needed with rasagiline or
selegiline (Weinreb et al., 2005).
Compound Molecules with MAO Inhibitory
and Neuroprotective Properties
Ladostigil (Weinstock et al., 2000) is a compound molecule
consisting of a molecule of rasagiline with the addition of a
propylcarbamatemoiety, which confers cholinesterase-inhibiting
properties. The combination of these two moieties in the same
molecule produced a drug with inhibitory properties on both
enzymes in vivo, while it is ineffective in vitro. An additional
fortuitous aspect of this molecule is that its MAO-inhibitory
property is brain-selective, so that the likelihood of cheese effect
is small. In rats, an oral dose of 75 µmoles/kg daily for 2 weeks
inhibits brain cholinesterase by 40% and brainMAO-A and –B by
70% with no significant inhibition of intestinal or hepatic MAO
(Weinstock et al., 2000), while higher doses can produce nearly
complete inhibition of brain MAO in several species (Youdim
et al., 2005).
The active metabolite of ladostigil responsible for the
cholinesterase-inhibitory activity is R-MCPAI (6-(N-methyl
carbamyloxy)-1(R)-aminoindan hydrochloride), which is
formed from ladostigil by CYP-2C19, while MAO inhibitory
activity in vivo is due to the metabolite R-HPAI (6-hydroxy-N-
propargyl-1(R)-aminoindan mesylate), since ladostigil itself does
not inhibit MAO in vitro. Recently the self-limiting inhibitory
effect of ladostigil on cholinesterases (maximal inhibition level
is 50–55%) has been studied in mice, and found to be the result
of rapid hydrolysis of the complex between R-MCPAI and the
enzyme, not by limitation in formation of R-MCPAI (Moradov
et al., 2015). A slow rate of conversion of ladostigil to R-HPAI
in the intestine prevents significant inhibition of intestinal
MAO, although following absorption of the parent molecule it is
converted to R-HPAI in the brain but to a lesser extent in other
tissues.
The drug was also found to possess a variety of
neuroprotective and cognitive effects in animal models (Weinreb
et al., 2012). Mechanistic studies showed that ladostigil binds to
the VDAC mitochondrial complex, protecting against reduction
in mitochondrial potential, and activates alpha-secretase leading
to production of the non-amyloidogenic form of soluble APP
by a MAP-Kinase dependent mechanism, in a similar way
to rasagiline (Yogev-Falach et al., 2002). Ladostigil possesses
anti-apoptotic properties against apoptosis induced by the
naturally-occurring neurotoxin N-methyl(R)salsolinol and the
peroxynitrite-generating molecule SIN-1 in SH-SY5Y cells
(Maruyama et al., 2003). It also possesses anti-inflammatory
properties as shown by its ability to reduce TNFα levels in
mouse spleen and macrophages, following LPS stimulation
(Moradov et al., 2015) and reduces the extent of gliosis and
memory deficits following streptozotocin-induced lesions of
the CNS in rats (Shoham et al., 2007). Ladostigil was tested
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in old rhesus monkeys for cognitive behavioral effects, and
was found to improve attention (Buccafusco et al., 2003).
Administered to stressed pregnant rats it corrected the
depressive behavior of the male offspring (Goelman et al.,
2014). The drug is currently in clinical trial for Mild Cognitive
Impairment (MCI).
Additional multi-target inhibitors of MAO have been
developed with the aim of incorporating iron-chelating activity
together with MAO inhibition (Wang et al., 2014). M30
and VAR10303 are both in development for clinical use in
neurodegenerative diseases. These compounds are relatively
selective inhibitors of brain as opposed to intestinal and liver
MAO, with similar degree of inhibitory activity on MAO-A and
MAO-B (Gal et al., 2005; Bar-Am et al., 2015). Unlike ladostigil,
M30 (Zheng et al., 2005) has potent MAO inhibitory activity in
vitro. The reason for the brain selectivity of these compounds has
not yet been determined.
ANTIPARKINSONIAN FEATURES OF
MAO-B INHIBITORS
Parkinson’s disease (PD) is a neurodegenerative disorder
primarily of the nigrostriatal DA-ergic pathway that affects the
motor system and results in symptoms including uncontrollable
tremor, muscle rigidity, slowness of movement (bradykinesia)
and postural instability (Lang and Lozano, 1998a). It is estimated
that it affects more than 4 million people worldwide (Schapira
et al., 2005), significantly shortens life, and affects quality of life
(Lang and Lozano, 1998a,b).
Much effort is being directed to development of new
drugs with neuroprotective properties for the treatment of
neurodegenerative diseases. Prior to initiating a new drug
development, evidence of target engagement is desirable. In
the case of putative neuroprotective therapies for PD this is
not readily accomplished. There are few targets in the CNS
that are associated with a possible pathogenic mechanism
and are accessible to drug treatment, although as described
above, MAOI have potential neuroprotective properties. Another
problem is that existing assessment scales have a limited
range and are particularly insensitive to detecting the modest
change in movement that occurs in the early stages of the
disease. Identification of a validated biomarker would be a
significant advance in diagnosis and objective measurement of
disease progression and drug efficacy. Recently Moloshnikov
and coworkers (Molochnikov et al., 2012) reported a disease
signature using blood RNA that detects idiopathic PD with
a sensitivity of 90%. This may help to improve the selection
of PD patients for clinical trials. The population of PD
patients selected for inclusion in clinical trials is also critically
important. Patients in early disease stages are frequently selected
because they are likely to have a larger number of remaining
neurons that can potentially be protected or rescued than
patients in advanced stages of the disease (Fearnley and Lees,
1991). In addition, patients in early stages of the disease
are generally still untreated which avoids the complication
of confounding drug action. There is, however, a greater
possibility of inaccurate diagnosis in early disease stage and a
higher risk of dropout if patients require treatment. Moreover,
disease progression is slower in the early stages of the disease,
possibly as a result of more efficient functional compensation
(Rascol et al., 2011).
Symptoms of PD are improved with DA–replacement
therapies such as DA receptor agonists and LD. Over time,
however, the benefit of these drugs fluctuates and patients begin
to experience loss of benefit with each dose of LD (wearing–
off) and involuntary dyskinesia. In addition some parkinsonian
symptoms including disturbances of gait and tremor may be
resistant to DA-ergic therapy.
The way in which selective inhibition of MAO-A or
MAO-B modifies DA release in vivo was studied in the rat
by microdialysis. Initial studies were made by single dose
administration using non-selective doses of the MAOI. The first
study to employ MAO subtype-selective doses of clorgyline,
selegiline, and rasagiline given chronically was carried out by
Lamensdorf and colleagues (Lamensdorf et al., 1996). This
study showed clearly that all three MAOI could increase striatal
extracellular levels of DA when given over 3 weeks, although
clorgyline caused the greatest elevation in DA levels. In a
later study by the same group (Lamensdorf et al., 1999), a
differential effect of selegiline was found to increase expression
of the DA transporter (DAT), whereas rasagiline and clorgyline
did not. In a follow-up study (Sader-Mazbar et al., 2013), the
effect of rasagiline and clorgyline on LD-induced DA levels
was studied in rats with a unilateral 6-hydroxydopamine (6-
OHDA) lesion of the substantia nigra. This study showed clearly
that clorgyline again was the most effective MAOI in causing
an increase in DA extracellular levels, although rasagiline also
elevated DA levels, in a dose level which was selective for MAO-
B inhibition. The superior effect of clorgyline in elevating striatal
extracellular DA levels is thought to be the result of inhibition
of the neuronal MAO, whereas the effectiveness of MAO-B
inhibitors in enhancement of LD-induced DA output in the
brain with a lesion of the DA-ergic neurons of substantia nigra
is thought to be the result of inhibition of glial cell MAO-B
(Carlo et al., 1996).
Inhibition of MAO-B may conserve the depleted synaptic
levels of DA, and delay the need for treatment with LD in patients
with early-stage PD. In patients with advanced-stage PD who
experience fluctuations in response to LD, MAO-B inhibition
potentiates and prolongs the effect of LD and permits use of a
lower dose (Riederer and Laux, 2011).
Irreversible MAOI selective for type B of the enzyme
are among the earliest drugs used in PD. They can be
used with or without LD (Riederer and Laux, 2011). Both
selegiline and rasagiline are beneficial in treating motor
symptoms in PD as monotherapy as well as in combination
with LD and a decarboxylase inhibitor. The main differences
between the two drugs are related to their metabolism,
interaction with cytochrome P450 enzymes and quantitative
properties at the molecular biologic/genetic level. Rasagiline
is more potent as shown in the daily dose necessary for a
symptomatic effect: selegiline 5–10mg daily and rasagiline 1mg
daily.
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Selegiline
Selegiline is a useful treatment for PD symptoms both in
monotherapy and as adjunct therapy to LD (Riederer et al.,
2004). However, selegiline undergoes first-pass metabolism to
R(−)amphetamine and R(−)methamphetamine, which have
the potential to cause cardiovascular and CNS adverse effects
(Gal et al., 2005). The contribution of these metabolites to
selegiline’s clinical symptomatic effects (Elsworth et al., 1982) and
the possibility of adverse cardiovascular reactions (Churchyard
et al., 1997), has often been discussed. R(−)amphetamine has
about one-tenth the activity of S(+)-amphetamine on the
sympathetic nervous system but the enantiomers are equivalent
in antagonism of DA uptake in the striatum (Coyle and
Snyder, 1969). One clinical study in which the effects of 10mg
of selegiline were compared with equivalent doses of R(−)-
amphetamine and R(−)-methamphetamine concluded that only
selegiline, and not its metabolites, possesses antiakinetic efficacy
in Parkinsonian patients (Elsworth et al., 1982). Moreover,
from documentation of side effects in the large clinical trials
of selegiline there is no evidence for enhanced cardiovascular
risk (Parkinson Study Group, 1989, 1993), as is true also when
selegiline is compared to treatment based on LD and DA receptor
agonists; however these drugs have never been studied in head-
to-head comparison. Long term trials have shown that 30–40%
of the daily LD dose can be reduced when the drug is combined
with selegiline (Birkmayer et al., 1975; Myllyla et al., 1997).
One interesting hypothesis about the good beneficial effect of
MAO-B inhibitors is that PEA, which increases in brain after
selegiline treatment (Reynolds et al., 1978), may have DA release-
promoting activity and by this way contribute to the positive
effects on motor features and behavior.
In 1989 Tetrud and Langston published a clinical study based
on the discovery that selegiline blocked the development of
MPTP-induced parkinsonism in laboratory animals, in which
they showed that in 22 PD patients medicated with selegiline
and 22 who received placebo the necessity to add LD (rescue
drug) occurred in the placebo group after 312.1 days and in the
selegiline group after 548.9 days (Tetrud and Langston, 1989).
In the DATATOP (Deprenyl and Tocopherol Antioxidative
Treatment of Parkinsonism) publications (Parkinson Study
Group, 1989, 1993) after 12 months of monotherapy with
selegiline or placebo (800 patients), 47% in the placebo group had
commenced LD therapy while in the selegiline group only 26%.
In addition it is important to mention that in the placebo group
the median length of time before patients needed LD was 454
days and in the selegiline group 719 days. In selegiline-treated
patients the need for addition of LD therapy was postponed by
∼9 months.
Shoulson et al. (2002) published interesting data concerning
long term follow up (7 years) of patients in the DATATOP group
treated with LD and selegiline, as well as those who received
placebo after 3–5 years treatment with selegiline. The conclusions
revealed that the wearing-off phenomenon did not improve in
the selegiline-treated patients but these patients had less on-off
phenomenon or freezing of gait and better motor features with
lower total UPDRS (Unified Parkinson’s Disease Rating Scores)
score. Activities of daily living (ADL), motor scores, LD dosages
and use of DA agonists were significantly reduced in the selegiline
groups. On the other hand, patients in the placebo group had less
dyskinesias than those on selegiline.
It is important to note that, in DATATOP and its extension
study it was impossible to distinguish between potential disease–
modifying (i.e., neuroprotective) and symptomatic benefits
of treatment (Parkinson Study Group, 1996a,b, 1989, 1993;
Shoulson et al., 2002). In another study (SELEDO), Przuntek
et al. (1999) showed that the length of time in which PD patients
treated with selegiline required an increase of 50% in LD dose
was 4.9 years, while in placebo-treated patients it was 2.6 years.
Myllyla et al. (1992, 1997) reported similar results.
The DATATOP results along with other earlier studies
demonstrated a modest symptomatic benefit with selegiline with
no significant difference between selegiline and placebo in the
occurrence of cardiovascular and other serious adverse events.
Long-term post-marketing data, however, have revealed that
orthostatic hypotension and hallucinations are seen frequently
in selegiline-treated patients, mainly in combination with LD
(Perez-Lloret et al., 2013).
A trial in 782 PD patients by the Parkinson’s Disease Research
Group of the United Kingdom (Lees, 1995; Ben-Shlomo et al.,
1998) concluded that the addition of selegiline to ongoing LD
therapy provided no additional clinical benefit but was associated
with increased motor complications and increased mortality.
A follow-up study from the same group examined postural
hypotension in a sub-group of patients and found that in 8 out
of 22 patients postural hypotension was exacerbated when on
selegiline, and this effect was abolished following withdrawal of
the drug (Churchyard et al., 1999). When experts who did not
participate in the study analyzed the results (Olanow et al., 1998)
they found that the conclusions reported were not correct and in
fact there was no increase in mortality with selegiline treatment
whether administered alone or in combination with LD (Olanow
et al., 1998). Considering selegiline treatment in randomized
studies it is important to mention a 157-patient, randomized
controlled Swedish study of selegiline long-term effects when
used in early PD either as monotherapy or in combination
with LD. This trial showed that at 7 years, selegiline-treated
patients had slower disease progression than their counterparts
as measured with UPDRS score. This outcome was observed in
the selegiline monotherapy PD patients as well as in those treated
in addition with LD (Palhagen et al., 2006), however also in
this study, the symptomatic effect of selegiline precludes drawing
conclusions about disease modification.
In general, summarizing most of the reports selegiline
is well tolerated. Side effects/adverse effects like nausea,
vomiting, sleeplessness, dry mouth, orthostatic hypotension and
dyskinesias have all been observed in the range of 2–5% of
PD patients (Parkinson Study Group, 1993; Reichmann et al.,
2000) which is comparable to placebo. Other side effects like
headaches, palpitations, dyspneas, confusion, edema, micturition
dysfunction, loss of appetite and anxiety have an incidence below
2% (Reichmann et al., 2000).
Waters et al (Waters et al., 2004) examined the effect of Zydis
selegiline in a 3 month, randomized, placebo-controlled study in
PD patients experiencing motor fluctuations in response to LD
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and found that it reduced off time by 2.2 h (compared with 0.6
h in the placebo group), without any increase in drug-related
adverse events.
Rasagiline
Rasagiline is a potent, selective, irreversible inhibitor of MAO-B
and in contrast to selegiline has no amphetamine-likemetabolites
(Finberg et al., 1999). Given in disease models relevant to PD
(Bar-Am et al., 2010), rasagiline showed good antiparkinsonian
and motor restoration activity as well as neuroprotection
properties, and its major metabolite 1-aminoindan is also
neuroprotective (see above section on Neuroprotection).
In a 10 week, randomized placebo-controlled pilot (phase 2)
trial of rasagiline in patients with early, untreated PD, a dose
of up to 4 mg/day was well tolerated. There were no cases
of hypertension, bradycardia or other cardiovascular adverse
experiences (Marek et al., 1997). One of the early randomized
clinical studies comparing rasagiline vs. placebo for advanced
PD patients was published in 2000 (Rabey et al., 2000). In
this study researchers planned to evaluate the safety, tolerability
and clinical effect of rasagiline as adjunct therapy with LD, in
a multicenter, double blind, placebo-controlled parallel group
study (0.5, 1, and 2 mg/day) lasting 12 weeks, in 70 patients
with PD (mean age 57.4 years, mean disease duration 5.7 years;
32 patients had motor fluctuations). A beneficial clinical effect
was observed in fluctuating patients treated with rasagiline (all
doses) and was expressed as a decrease in total UPDRS score
(by 23% in rasagiline-, 8.5% in placebo-treated subjects). The
anti-Parkinsonian effect of rasagiline was still evident 6 weeks
after stopping treatment at all dose levels. The incidence of
adverse effects with rasagiline was similar to those on placebo.
Determination of platelet MAO activity (MAO-B) showed nearly
complete MAO-B inhibition at all rasagiline dose levels. This
study showed that rasagiline (up to 2 mg/day) is well-tolerated
and has a beneficial clinical effect in fluctuating patients with PD
when given together with chronic LD therapy.
In the TEMPO (Rasagiline mesylate in Early Monotherapy
for Parkinson’s disease Outpatients) study (Parkinson Study
Group, 2002), 404 de novo (untreated) PD patients received
either placebo (n = 138), rasagiline 1mg per day (n = 134) or
rasagiline 2mg per day (n = 132) for 26 weeks. All the patients
receiving rasagiline showed statistically significant improvement
compared with placebo in the mean change from baseline of the
Unified Parkinsons’s Disease Rating Scale (UPDRS part I-III) by
4.2 and 3.6 points, in 1 and 2mg/day groups respectively. Patients
on rasagiline showed also a significant and beneficial effect for
quality of life as assessed by the Parkinson’s Disease Quality of
Life (PD-QUALIF) scale.
Considering the results of preclinical studies which suggested
that rasagiline may modify the progression of PD (Maruyama
et al., 2001; Akao et al., 2002), the TEMPO study was extended
into a delayed start trial comparing the effects of early and
later initiation of rasagiline on disease progression (Parkinson
Study Group, 2004). Three hundred seventy–one subjects from
the TEMPO study were included in the 1-year efficacy analysis.
Patients who had received rasagiline 1 or 2 mg/day for 6 months
received the same dose for a further 6 months, while those
who had been treated with placebo for 6 months were given
rasagiline 2 mg/day for a further 6 months. This design was
adopted in order to compensate for the symptomatic effect of
rasagiline, which prevented concluding that the drug had a
disease-modifying action when rasagiline-treated patients were
compared with those treated with placebo. In this delayed-start
trial, it was possible to compare patients who had received
rasagiline 2 mg/day for 12 months with those who had received
this dose for only 6 months, but all were receiving the drug at
the time of neurological assessment at 12 months from start. The
result of this trial was that patients who had received rasagiline 2
mg/day for 12months had a 2.29-unit smaller increase in UPDRS
score than those who were treated with rasagiline 2 mg/day for
6 months (P = 0.01). This delayed-start analysis suggested that
rasagiline could have a disease-modifying activity.
The ability of rasagiline to improve LD response in more
advanced PD patients with motor fluctuations was studied in
LARGO (Lasting effect in Adjunct therapy with Rasagiline Given
Once daily) (Rascol et al., 2005). In this study 231 individuals,
received rasagiline (1mg daily), 229 received placebo, and 227
received entacapone (200mg daily). All were treated with LD
and a decarboxylase inhibitor. The primary outcome was change
in total daily off-time. Other measures included the (CGI) score
and the UPDRS scores. Both rasagiline and entacapone reduced
mean daily off-time (−1.18 h rasagiline and −1.2 h entacapone
vs. placebo −0.4). A significant improvement in clinical global
improvement (CGI) scores, and activities of daily living during
off-time and motor function during on time was seen with both
rasagiline and entacapone. Adverse effects were similar in all
groups.
To date the majority of PD clinical studies conducted in
patients with motor fluctuations have reported the duration of
OFF time during the day with limited evaluation of the severity
of PD symptoms during ON time. The irreversible nature of
the binding of rasagiline to the essential cofactor of the active
site of the MAO-B enzyme means that the duration of its
therapeutic action is independent of the drug’s half-life and is
instead determined by the regeneration rate ofMAO-B (Thebault
et al., 2004). The Largo study included a subgroup of patients,
“UPDRS motor OFF substudy,” for which there was a separate
informed consent form. Patients included in this sub-study, were
receiving optimum LD + decarboxylase inhibitor therapy, were
stable for at least 14 days before study start, and experienced
motor fluctuations in which they were in OFF state for at
least 1 h every day not including morning akinesia. Additional
antiparkinsonian therapy was accepted, with the exception of
selegiline, tolcapone and previous treatment with entacapone.
At the start of the 18 weeks study patients were randomly
assigned to receive placebo, rasagiline 1mg or entacapone 200mg
in addition to LD and decarboxylase inhibitor. The LD dose
could be reduced during the first 6 weeks if dyskinesia worsened.
Thereafter the LD dose remained the same for the final 12 weeks
of the study (Stocchi and Rabey, 2011). Treatment with rasagiline
produced a significant improvement over placebo of 5.64 units in
UPDRS motor OFF score (P = 0.013 vs. placebo). By contrast
the effect of adjunct entacapone was not significant (P = 0.14 vs.
placebo). Retrospective analysis using the Bonferroni correction
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of UPDRSmotor subdomains further revealed that rasagiline but
not entacapone, significantly improved bradykinesia (p < 0.001)
and showed a trend for improvement in facial expression, speech
and axial impairment during OFF time.
In Olanow et al. (2009) conducted a double blind study,
with early and delayed start rasagiline (Attenuation of Disease
Progression with Rasagiline Given Once-daily, ADAGIO), in
order to establish more substantially whether this drug has
disease-modifying effect in PD. A total of 1091 untreated PD
patients participated in the start of the study; 273 early start
rasagiline 1 mg/day, 270 delayed start rasagiline 1 mg/day, 273
early start rasagiline 2 mg/day, and 275 delayed start rasagiline 2
mg/daily. The early start group received the drug for 72 weeks,
the delayed start group received placebo for 36 weeks followed by
rasagiline for a further 36 weeks.
The putative result required for disease-modification is shown
diagrammatically in Figure 1
Three endpoints were required to be met in order to permit
a positive result: (a) increased slope of the decline in UPDRS
in the placebo group with respect to the rasagiline group in
the first phase of the study (i.e., week 12–36); (b) a difference
between the early- and delayed-start groups in the change in
UPDRS score between weeks 12 and 72, and (c) similarity of the
slopes of change in UPDRS score with time in the period between
weeks 48 and 72. Finite values of UPDRS were fixed for the three
endpoints. The conclusions of the study were: “Early treatment
with rasagiline at a dose of 1mg per day provided benefits that
were consistent with a possible disease-modifying effect, but early
treatment with rasagiline at a dose of 2mg per day did not.
Because the two doses were associated with different outcomes,
the study results must be interpreted with caution” (Churchyard
et al., 1999).
Following publication of the Adagio results, there has been
much discussion about the significance of the data. Rascol
et al. published in 2011 a secondary and post-hoc comment on
FIGURE 1 | Schematic of ADAGIO delayed start neuroprotection trial of
rasagiline. Treatment with placebo (delayed start group) or rasagiline (early
start group) was commenced at time 0. At week 36, the placebo group was
changed to rasagiline, and the rasagiline group continued with rasagiline.
Adapted from Olanow et al. (2009).
the ADAGIO study (Rascol et al., 2011). In addition to the
criterion of UPDRS score, they included changes in non-motor
experiences of daily living (ADL), fatigue scales, the need for
additional antiparkinsonian therapy, and (UPDRS) subscores, in
the data assessment. In addition to the finding that rasagiline
therapy delayed the need for additional antiparkinsonian drugs,
and improved ADL scores in the 1 mg/daily early start group,
they showed that the rate of deterioration in UPDRS scores
correlated with baseline scores, patients with low baseline scores
deteriorating slower than those with higher baseline scores.
A difference in the distribution of low and high baseline
UPDRS scores between the 1 and 2mg daily groups could have
contributed to the lack of difference between early and late start
groups at the 2mg dose level.
In 2014, Jankovic et al. (2014) published another post-hoc
analysis from the ADAGIO study in which they examined the
responses of patients to rasagiline 1 mg/day (n= 288) with those
to placebo (n = 588) on key motor symptoms at 36 weeks. In
the rasagiline group, significantly better tremor, bradykinesia,
rigidity and postural-instability-gait difficulty scores were seen
at week 36 by comparison with placebo. While the placebo
group deteriorated from baseline by 2.6 points UPDRS at week
36, patients in the rasagiline group improved initially but then
returned to baseline values at week 36. At week 72 patients
who had received continuous monotherapy with rasagiline
experienced a worsening of only 1.6 points. The conclusions
of this analysis were that treatment with rasagiline maintained
motor function at baseline values for at least a year with
significant benefit observed in all key PD motor symptoms.
Safinamide
Safinamide, an orally active alpha-aminoamide derivative, is a
novel reversible and highly selective MAO-B inhibitor which is
efficacious as add-on therapy to DA agonists in early-stage PD
(Stocchi et al., 2004, 2012) and as adjunct to LD in mid- to late-
stage PD (Borgohain et al., 2014). In addition toMAO inhibition,
the molecule possesses additional pharmacological properties,
including state-dependent blockade of voltage-gated sodium and
calcium channels, and inhibition of glutamate release in rat
hippocampal synaptosomes (Caccia et al., 2006; Stocchi et al.,
2006). These properties may be responsible for its demonstrated
neuroprotective effect in laboratory animals.
The use of safinamide as adjunct therapy to LD was
investigated in mid- to late-stage PD patients with motor
fluctuations (Waters et al., 2004). In an initial 6 month trial,
safinamide 50mg (n = 197) or 100mg (n = 195) daily was
studied in relation to placebo (n = 197) and was found to
significantly increase ON time without increasing dyskinesia.
The study was then continued in the same patient population
for an additional 18 months. In the final evaluation of the 2
year period, both safinamide groups had a significant increase
in ON-time compared to placebo, which was maintained over
the period between 24 and 102 weeks. A non-significant
reduction in Dyskinesia Rating Score (DRS) was found for
both safinamide groups, but in considering this result, 74%
of the population had no to mild dyskinesia at baseline.
In the case of the sub-group with more severe dyskinesia
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(DRS > 4, 36% of the population), safinamide caused a
reduction in DRS in relation to placebo, which was significant
(P = 0.0317) at the 100mg daily dose level. Other benefits
noted by the investigators in the safinamide group included
improvements in ADL, depression, clinical status and quality
of life (Borgohain et al., 2014). In an efficacy study reported
by Schapira et al. (2013) patients received 100 mg, 200mg
safinamide or placebo added to LD, or DA agonists. In their
study the conclusions were that the safinamide group did not
attain the primary endpoint of increase in time required for
additional drug therapy, however post hoc analysis showed that
safinamide was effective in PD therapy in combination with DA
agonists.
A number of research groups are aiming to develop other
MAO-A and MAO-B reversible inhibitors. A series of chalcone
derivatives with reversible MAO-A and MAO-B selective
properties was recently described (Minders et al., 2015). The IC50
of the most potent MAO-B inhibitor in this series was 0.067 µM,
by comparison with 0.098 µM for safinamide. Further data on in
vivo metabolism and efficacy will be required to see whether this
compound has therapeutic potential.
CONCLUSIONS
Today there is a broad spectrum of therapeutic possibilities for
the utilization of MAO-A and -B inhibitors, for the management
of PD, and also for the treatment of depression. Novel routes
of administration, as well as pro-drugs which are converted to
active inhibitors by brain enzymes, are promising directions for
development of MAOI with selective action in the brain in order
to avoid cheese effect. New drug developments which combine
different types of activity in the same molecule, and can possibly
be effective in more than one disease condition, may be useful in
treatment of both neuropsychiatric and neurological disorders,
and mechanism-based drug combinations may improve efficacy
in PD and other diseases
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